Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,608,973 papers from all fields of science
Search
Sign In
Create Free Account
PF-05280014
Known as:
Trastuzumab Biosimilar PF-05280014
, Trastuzumab Biosimilar ABP 980
, Herceptin Trastuzumab Biosimilar PF-05280014
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Antibodies, Monoclonal, Humanized
trastuzumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Author response for "Pharmacokinetic and Pharmacodynamic Bioequivalence of Proposed Biosimilar MYL‐1501D With US and EU Insulin Glargine Formulations in Patients With Type 1 Diabetes Mellitus"
T. Heise
,
Charles Donnelly
,
Abhijit Barve
,
P. Aubonnet
2019
Corpus ID: 214220784
2018
2018
Umstellung auf Biosimilar ohne Wirkverlust
A. Ameri
Gastro-News
2018
Corpus ID: 57905307
2018
2018
TGF-β2 in human milk research: Exploration of a new field methodology and new findings of biosimilar TGF-β2 in non-human milk
C. Sweetman
2018
Corpus ID: 92658484
2016
2016
Biosimilar Therapeutic Monoclonal Antibodies Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval , Part 2
S. Kaur
,
Darryl Sampey
,
Lester Schultheis
,
L. Freedman
,
W. Bentley
2016
Corpus ID: 7550665
Last month, Part 1 of this discussion brief ly described the regulatory landscape for developing biosimilar therapeutic…
Expand
2015
2015
Sale of biosimilar Zarxio delayed until at least June 3
J. Talsma
2015
Corpus ID: 70775467
Although the biosimilar Zarxio (filgrastim-sndz,) was approved in March, the manufacturer, Sandoz/Novartis, has been delayed from…
Expand
2014
2014
Rheumatoide Arthritis – Infliximab und Biosimilar vergleichbar?
Anika-Maria Obry
Aktuelle Rheumatologie
2014
Corpus ID: 80354605
Akt Rheumatol 2014; 39 Die amerikanischen Autoren der University of Washington / Seattle, überprüften ihre Hypothese anhand den…
Expand
2013
2013
Abstract OT1-1-03: A phase 3 randomized, double-blind trial comparing PF-05280014 + paclitaxel vs. trastuzumab + paclitaxel for treatment of HER2+ metastatic breast cancer patients
R. Ewesuedo
,
K. Barker
,
C. Taylor
,
I. Jacobs
2013
Corpus ID: 71931912
Background: PF05280014 is being developed as a potential biosimilar to trastuzumab. PF-05280014 demonstrated similarity to…
Expand
2012
2012
Abstract OT1-1-05: A Phase I pharmacokinetics trial comparing PF-05280014 and trastuzumab in healthy volunteers (REFLECTIONS B327-01)
A. Ricart
,
C. Zacharchuk
,
+4 authors
Arne G. Hansson
2012
Corpus ID: 71347818
Background: Trastuzumab is a humanized recombinant monoclonal antibody that selectively binds the extracellular domain of human…
Expand
2011
2011
The New and Improved (?) Activated Factor VII Molecules The Clinical Development Challenges of Recently Announced Modified and Biosimilar rFVIIas
A. Retzios
2011
Corpus ID: 80132727
2009
2009
Biosimilar epoetins. Author's reply
I. Macdougall
,
A. Covic
2009
Corpus ID: 78620663